1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

31 Jul 2025
Admin
News Article

Strides Pharma Delivers Strong Q1 FY26 Results with 80% Surge in Profit

Strides Pharma Science posted robust numbers in its Q1 FY26 results, reflecting sharp gains in profitability and steady revenue growth.

Key Highlights from Q1 FY26 (Ended June 30, 2025)

Revenue Performance
- ₹1,119.7 crore in consolidated revenue.
- 6.2% YoY growth from ₹1,054.6 crore in Q1 FY25.
EBITDA Metrics
- ₹218.1 crore EBITDA, up 14.8% YoY.
- EBITDA margin at 19.5%, a 150 basis point improvement YoY.
Profit After Tax
- Operational PAT surged to ₹114 crore, marking an 80.6% YoY increase.
- Reported PAT stood at ₹105.6 crore.
- Operational EPS reached ₹12.4.
Return on Capital Employed (ROCE)
- ROCE improved to 15.1% for the quarter.
US Market Revenue
- $71 million in sales, a 7% increase YoY.

CEO's Statement

Badree Komandur, MD & Group CEO, commented:

“We are pleased to report a solid start to the year, marked by consistent growth and enhanced profitability. Cost control and operational discipline fueled strong results.”

He added:

“The EBITDA margin expanded to 19.5%, and the company posted its highest-ever quarterly PAT. We will ramp up R&D investments to fuel long-term growth.”

Outlook

Strides aims to sustain this momentum by:

Enhancing R&D initiatives.
Maintaining cost efficiencies.
Strengthening presence in key markets like the US.

The quarter positions Strides Pharma on a solid path for FY26, balancing immediate gains with long-term investment.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!